C Peptide Suppression Test

• The C Peptide Suppression Test assesses endogenous insulin production by measuring C-peptide levels.
• It is primarily used to diagnose insulinoma, a rare tumor that produces excessive insulin, and to investigate causes of hypoglycemia.
• The test involves administering exogenous insulin and monitoring the subsequent suppression of C-peptide.
• Normal results show significant C-peptide suppression, while a lack of suppression suggests autonomous insulin secretion.
• Interpretation of results helps differentiate between various causes of low blood sugar, guiding appropriate treatment.

What is C Peptide Suppression Test?

The C Peptide Suppression Test is a diagnostic tool employed in endocrinology to assess the body’s endogenous insulin production. C-peptide is a byproduct released in equal molar amounts with insulin when proinsulin is cleaved in the pancreas. Measuring C-peptide provides an accurate reflection of how much insulin the pancreas is producing, even when exogenous insulin is present in the body. This test is particularly valuable for investigating conditions characterized by hypoglycemia, or abnormally low blood sugar, where the underlying cause of insulin overproduction needs to be identified.

Unlike direct insulin measurements, C-peptide levels are not affected by therapeutic insulin injections, making it a reliable marker for the pancreas’s own insulin secretion. By observing how C-peptide levels respond to external insulin administration, clinicians can determine if the pancreas is autonomously producing insulin, which is a key indicator for certain medical conditions.

Purpose and Procedure of the Test

The primary c peptide suppression test purpose is to diagnose insulinoma, a rare neuroendocrine tumor of the pancreas that secretes excessive amounts of insulin, leading to recurrent hypoglycemia. It is also used to differentiate between other causes of hypoglycemia, such as factitious hypoglycemia (self-administration of insulin or sulfonylureas) or non-insulinoma pancreatogenous hypoglycemia syndrome (NIPHS). The test helps determine if the body’s insulin production can be appropriately suppressed by external factors.

Understanding how c peptide suppression test works involves a carefully controlled clinical procedure. Patients typically fast overnight before the test. The procedure generally follows these steps:

• A baseline blood sample is collected to measure initial glucose and C-peptide levels.
• A continuous intravenous infusion of exogenous insulin is administered. This insulin infusion is designed to lower blood glucose levels and, in a healthy individual, should suppress the pancreas’s own insulin production.
• Blood samples are collected at regular intervals (e.g., every 15-30 minutes) over several hours to monitor glucose and C-peptide levels.
• The test is usually continued until blood glucose levels fall below a certain threshold (e.g., 40 mg/dL or 2.2 mmol/L) or for a predetermined duration, typically up to 3 hours, to observe the C-peptide response to induced hypoglycemia.

Throughout the test, patients are closely monitored for symptoms of severe hypoglycemia, and glucose can be administered if necessary to ensure patient safety. The goal is to create a state of hypoglycemia that would normally trigger a significant reduction in endogenous insulin (and thus C-peptide) secretion.

Interpreting C Peptide Suppression Test Results

The c peptide suppression test interpretation relies on observing the relationship between induced hypoglycemia and C-peptide levels. In a healthy individual, as blood glucose levels drop due to exogenous insulin, the pancreas should reduce its own insulin production, leading to a significant suppression of C-peptide levels. A normal response is typically defined as C-peptide levels suppressing to below a certain threshold, often around 0.6 ng/mL (0.2 nmol/L), during the hypoglycemic phase.

Conversely, a lack of appropriate C-peptide suppression in the presence of hypoglycemia is indicative of autonomous insulin secretion, meaning the pancreas is producing insulin independently of the body’s glucose levels. This finding is highly suggestive of an insulinoma. The following table summarizes typical interpretations:

This test provides critical information for clinicians to accurately diagnose and manage conditions causing hypoglycemia, guiding decisions on further imaging studies or surgical interventions for insulinomas. It helps distinguish between conditions where insulin production is appropriately regulated and those where it is pathologically excessive.